

## **FOR IMMEDIATE RELEASE:**

### **EBI CLOSES \$6.25 MILLION IN EQUITY FINANCING**

**Washington DC, October 17, 2005** — Privately held Exponential Biotherapies, Inc. ("EBI"), a Washington DC based drug discovery and development company, today announced that it has completed equity financing totaling \$6.25 million as the first tranche of an anticipated total package totaling \$8.75 million from a Netherlands limited liability company. The second tranche of \$2.5 million is expected to close on March 31, 2006. Together with Xavier Holdings Company LTD of The Bahamas, a FORTIS Company (FORTIS is the major Benelux banking and insurance group that ranks among the top 20 financial institutions in Europe with a market capitalization of almost €25 billion) and Reserve Holdings LTD of Costa Rica, EBI has completed approximately \$17 million in new equity financing over the last 2 years. Since inception, EBI has raised approximately \$34 million of equity capital.

This financing provides the Company with the resources to advance our pipeline and research activities through several key milestones," said Bob Berns, J.D. EBI's CFO.

EBI is a privately held, Washington DC based drug discovery and development company with a growing pipeline of novel small molecule drugs designed to treat a wide range of severe inflammatory disorders such as septic shock, radiation sickness and avian influenza. These compounds represent a new class of immune regulating therapeutic agents.

### **Forward-looking statements**

This press release contains forward looking statements, including statements related to our clinical trials and product candidates. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these or other risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials; risks that subsequent clinical trials may show candidate compounds and applications are not safe and/or effective; issues relating to the intellectual property upon which our drug candidates are dependent; difficulties or delays in obtaining regulatory approval or clearance which are necessary or advisable in the conduct of future clinical trials or are necessary for the commercialization of any of our product candidates; manufacturing issues relating to any of our drug candidates; our ability to obtain financial resources necessary to support our clinical trials, other operations and financial commitments; competitive issues; and other regulatory considerations which affect the business prospects of EBI. Given these and other uncertainties, you should not place undue reliance on these forward-looking statements.

### **Contact**

Bob Berns, J.D., Director and CFO 703-883-3701